trial

Phase I Study to Evaluate the Safety and Pharmacokinetics of Oral Doses of Anvylic-3288 in Healthy Subjects

NCTId NCT01851603
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 1 · Terminated
Enrollment 12 (actual)
Sponsored by University of Colorado, Denver
Primary completion 2016-08
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 1
Status
Terminated
Enrollment
12 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Quadruple
Start
2013-06
Primary completion
2016-08
Eligibility
MALE · 18 Years · 70 Years

Interventions & indications

Drugs
AVL-3288

Sponsors

University of Colorado, DenverLead Sponsor
National Institute of Mental Health (NIMH)Collaborator

Investigators

1
Robert Freedman, MDPrincipal Investigator

Sites

1 total
Aurora, United States

Facts & assertions

4 sourced
Enrollment
12
Phase
PHASE1
Primary Completion Date
2016-08
Status
TERMINATED
relationships
The graph out of here
drug
AVL-3288
drug
lead_sponsor
University of Colorado, Denver
company
collaborator
National Institute of Mental Health (NIMH)
company
indication
Schizophrenia
indication
Schizophrenia
indication
investigator
Robert Freedman, MD
person